26 July 2018
SEGRO plc today announces its results for the six months ended 30 June 2018….
Over the first half, the strong sales growth from new medicines and the continued strength of the Emerging Markets business were offset by the impact from the loss of Crestor exclusivity in Europe and Japan. …
In the first six months of 2018, the Group continued to perform well. The cigarettes and THP portfolio has outperformed the industry as market share grew 40 basis points (bps) with a tobacco price mix of approximately 4% which is expected to strengthen in the second half of the year. …
Strong performance reflects consistent and rigorous execution of our strategy
…
SUMMARY OF UNAUDITED RESULTS …
July 26, 2018
Royal Dutch Shell plc (the ‘company’) today announces the immediate start of a share buyback programme in accordance with authority granted by shareholders at the company’s 2018 Annual General Meeting….
HIGHLIGHTS Record revenue of £611.5m, with growth at constant exchange rates of 18% Revenue growth in all metrology product lines. Revenue growth in all healthcare product lines. Record adjusted profit before tax of £145.1m, with growth of 33% Healthcare business achieves profit for the first time, with adjusted profit before tax of £0.3m (2017: £7.2m loss) Capital expenditure of £34.9m, providing for future growth Strong balance sheet, with cash of £103.8m, compared with £51.9m last year Dividend increased by 15% to 60.0p…
25 July 2018
GSK delivers improvements in sales (at CER), margins and cash flow in Q2 2018
Total EPS 9.0p, >100% AER, >100% CER; Adjusted EPS 28.1p, +3% AER, +10% CER
GSK sets out new approach to Research and Development and upgrades 2018 EPS guidance…